News | Antiplatelet and Anticoagulation Therapies | May 25, 2016

Technavio Projects Top U.S. Anticoagulant Trends Through 2020

Company says new therapeutic uses, patient assistance programs and the decline of heparin’s market share will shape market through the rest of the decade

anticoagulants, U.S. market, Technavio, 2020, trends

May 25, 2016 — Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

The top three emerging trends driving the anticoagulants market in the United States, according to Technavio healthcare and life sciences research analysts, are:

  • Expected exploitation of new therapeutic use;
  • Patient assistance programs; and
  • Declining shares of heparin market.


Expected exploitation of new therapeutic use

Heparin and related drugs are widely used for their anticoagulant activities. However, it has been identified that heparin exhibits anti-inflammatory activities and prevents the metastatic spread of tumor cells. Heparin exhibits anti-inflammatory activity by neutralizing cationic mediators, inhibiting adhesion molecules and heparanase, which are involved in leukocyte recruitment into tissues. Similarly, research studies indicate that heparin acts as an inhibitor of cell adhesion and elicits anti-metastatic activities. The drug is also found to target P- and L-selectin, and integrin activity, preventing cancer progression. Further studies are being conducted to exploit the use of heparin as an anti-inflammatory and antitumor agent. With frequent innovations there has been an increase in the development of heparin drugs as novel formulations and for the treatment of new indications.

“Ockham Biotech is developing inhaled heparin for the treatment of airway diseases, cystic fibrosis and asthma either alone or in combination with other drugs under various stages of development. Also the LMW Heparin MMX, which is under the Phase II stage of development by Cosmo Pharmaceuticals, is indicated for the treatment of ulcerative colitis,” said Barath Palada, a lead analyst at Technavio for cardiovascular and metabolic disorders research.


Patient assistance programs

Patient assistance programs for anticoagulants are expected to boost the growth of the market during the forecast period. The vendors in the market are providing co-pay assistance to patients who are purchasing the indicated medications for coagulation disorders. For instance, Daiichi Sankyo’s drug Savaysa has an assistance program to provide financial assistance to those consuming the drug. According to the support program, eligible patients are provided with a Savaysa Savings Card, which is available at $4 for a 30-day prescription and at $12 for a 90-day prescription. However, individuals who are enrolled for the Medicare/Medicaid program are not eligible for this savings program. Similarly, BMS provides assistance to patients buying its drugs through the Bristol-Myers Squibb Patient Assistance Foundation.

Only residents of the United States who are not insured under any other public or private insurance are eligible for assistance under this scheme. Apart from these, Janssen’s Xarelto CarePath Savings Card and Boehringer Ingelheim’s Pradaxa Savings Card allow eligible patients to acquire the drugs with minimum payment. “Since such assistance programs are provided by the drug suppliers, patients feel inclined toward purchasing branded therapies,” said Barath.


Declining shares of heparin market

The share of the heparin drugs market, which constitutes over half of the overall anticoagulants market, is declining at a significant rate owing to the availability of improved drugs in the market. This has reduced the overall heparin production, especially in developed countries because of shrinking demand from end-users. China remains the largest heparin active pharmaceutical ingredient (API) producer in the world and has a share of 80 percent of the global heparin API market. The market grew exponentially till 2009, and then experienced a decline due to the restrictions imposed after the 2008 adulterated heparin disaster, which led to the loss of hundreds of lives. This led to a decline in demand for heparin in Western countries and increased the regulatory standards for heparin API. However, the market has been experiencing slow growth in terms of the volume of heparin API being exported to other countries.

For more information:

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init